Apellis Pharmaceuticals's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Apellis Pharmaceuticals is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is €-0.42. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 146.38M	$ 110.40M	$ 89.64M	$ 44.85M	$ 22.66M
Gross Profit	$ 139.98M	$ 110.40M	$ 94.97M	$ 44.85M	$ 19.74M
EBIT	$ -88.95M	$ -139.11M	$ -120.95M	$ -169.97M	$ -159.72M
EBITDA	$ -88.39M	$ -138.57M	$ -120.45M	$ -169.47M	$ -159.30M
Net Income Common Stockholders	$ -88.58M	$ -88.11M	$ -122.04M	$ -177.78M	$ -165.99M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 351.20M	$ 452.40M	$ 617.38M	$ 766.38M	$ 551.80M
Total Assets	$ 788.73M	$ 818.22M	$ 915.61M	$ 978.87M	$ 760.22M
Total Debt	$ 110.93M	$ 109.58M	$ 110.80M	$ 111.87M	$ 112.71M
Net Debt	$ -240.27M	$ -342.82M	$ -506.58M	$ -654.50M	$ -439.09M
Total Liabilities	$ 594.21M	$ 585.95M	$ 570.17M	$ 566.75M	$ 590.35M
Stockholders Equity	$ 194.52M	$ 232.27M	$ 354.08M	$ 412.12M	$ 169.87M
Cash Flow	-
Free Cash Flow	$ -97.87M	$ -169.13M	$ -150.53M	$ -177.88M	$ -141.59M
Operating Cash Flow	$ -97.88M	$ -169.09M	$ -150.16M	$ -177.62M	$ -140.74M
Investing Cash Flow	$ 4.00K	$ -47.00K	$ -372.00K	$ -259.00K	$ 124.13M
Financing Cash Flow	$ -3.91M	$ 5.75M	$ 1.56M	$ 391.11M	$ -15.95M

Currency in USD

Apellis Pharmaceuticals Earnings and Revenue History

Income Statement >

Apellis Pharmaceuticals Debt to Assets

Balance Sheet >

Apellis Pharmaceuticals Cash Flow

Cash Flow >

Apellis Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing